Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes Joint Steering Committee between Launch Therapeutics and Gilead Sciences London, UK and New York, USA, February 29, 2024 - Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today announced a strategic...

Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF) Abingworth extends its capital base for late-stage clinical programs with pharma and biotech partners London, UK and New York, USA, October 30, 2023 - Abingworth, a leading international life...